Monique J L Mastboom1, Emanuela Palmerini2, Floortje G M Verspoor3, Anja J Rueten-Budde4, Silvia Stacchiotti5, Eric L Staals6, Gerard R Schaap7, Paul C Jutte8, Will Aston9, Hans Gelderblom10, Andreas Leithner11, Dietmar Dammerer12, Akihiko Takeuchi13, Quirina Thio14, Xiaohui Niu15, Jay S Wunder16, Michiel A J van de Sande17. 1. Department of Orthopaedics, Leiden University Medical Center, Leiden, Netherlands. Electronic address: mjlmastboom@lumc.nl. 2. Medical Oncology, Musculoskeletal Oncology Department, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy. 3. Orthopaedic Surgery, Radboud University Nijmegen Medical Center, Nijmegen, Netherlands. 4. Mathematical Institute, Leiden University Medical Center, Leiden, Netherlands. 5. Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy. 6. Orthopaedic Surgery, Musculoskeletal Oncology Department, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy. 7. Orthopaedic Surgery, Academic Medical Center, Amsterdam, Netherlands. 8. Department of Orthopaedics, University Medical Center, University of Groningen, Groningen, Netherlands. 9. Orthopedic Surgery, Royal National Orthopedic Hospital, London, UK. 10. Medical Oncology, Leiden University Medical Center, Leiden, Netherlands. 11. Department of Orthopaedic Surgery, Medical University Graz, Graz, Austria. 12. Orthopedic Surgery, Medical University of Innsbruck, Innsbruck, Austria. 13. Orthopaedic Surgery, Kanazawa University Graduate School of Medical Sciences, Kanazawa, Japan. 14. Orthopedic Surgery, Massachusetts General Hospital Harvard, Boston, MA, USA. 15. Department of Orthopedic Oncology, Beijing Jishuitan Hospital, Beijing, China. 16. University Musculoskeletal Oncology Unit, Mount Sinai Hospital, Toronto, ON, Canada. 17. Department of Orthopaedics, Leiden University Medical Center, Leiden, Netherlands.
Abstract
BACKGROUND: Diffuse-type tenosynovial giant-cell tumour is a rare, locally aggressive, and difficult-to-treat soft tissue tumour. Clinical and surgical outcomes depend on multiple factors, including preoperative diagnostic assessment, the localisation and extent of disease, and possibly the choice of treatment modalities by orthopaedic surgeons. We did a retrospective cohort study to characterise global surgical treatment protocols, and assess surgical outcomes, complications, and functional results in patients with diffuse-type tenosynovial giant-cell tumours. METHODS: In this international, multicentre, retrospective cohort study, we included consecutive patients treated in 31 sarcoma reference centres between Jan 1, 1990, and Dec 31, 2017. Eligible patients were of any age and had histologically proven diffuse-type tenosynovial giant-cell tumour of large joints. Patient data were retrieved from the local databases of participating centres. Patients with localised-type tenosynovial giant-cell tumour were excluded. In the analysis, we only included patients with complete core criteria data regarding admission status, date of treatment, type of treatment at participating centre, and first local recurrence after treatment. We used a non-parametric method to estimate recurrence-free survival at 3, 5, and 10 years after initial surgical resection in a tertiary centre. We used a multivariate Cox regression model to estimate the effect of risk factors. We also present subgroup analyses of disease status at presentation (primary vs recurrent disease) and recurrence-free survival by surgery type (open surgery vs arthroscopic synovectomy), and prespecified risk factors were tested in a univariate and multivariable analyses, with an endpoint of first local recurrence after treatment in a tertiary centre. FINDINGS: Data collection for these analyses occurred between January, 2016, and May, 2018. We received the records of 1192 patients, of which 966 (81%) were surgically treated and had complete information on core criteria. 445 patients were admitted with therapy-naive disease of the knee and were primarily treated in a tertiary centre. Since patients with wait and see treatment do not have a starting date of treatment, these patients were excluded in the calculation of median follow-up time for all patients. For this calculation we used time of surgery as a starting date. 758 (64%) of 1192 patients had knee involvement and 628 (54%) of 1163 patients with complete data on type of surgery had one-staged open synovectomy. At a median follow-up of 54 months (IQR 27-97), recurrent disease developed in 425 (44%) of all 966 surgically treated cases, and recurrence-free survival was 62% (95% CI 59-65) at 3 years, 55% (51-58) at 5 years, and 40% (35-45) at 10 years. Surgical complications were reported in 105 (12%) of 906 patients who had complete data on surgical complications. Pain improved after surgical treatment in 255 (59%) of 434 patients and swelling improved in 328 (72%) of 453 patients who had complete data. INTERPRETATION: This study of patients with diffuse-type tenosynovial giant-cell tumour provides a comprehensive and up-to-date disease overview, assessing the clinical profile and management of the disease in multiple specialised referral centres. Surgical treatment of diffuse-type tenosynovial giant cell tumours is not a definitive treatment for every patient because it involves a high risk for local recurrent disease and a relatively high risk for postoperative complications. After surgical treatment in treatment-naive patients, risk factors for recurrent disease in individual patients were not identified in what we believe is the largest cohort to date. FUNDING: Daiichi Sankyo.
BACKGROUND: Diffuse-type tenosynovial giant-cell tumour is a rare, locally aggressive, and difficult-to-treat soft tissue tumour. Clinical and surgical outcomes depend on multiple factors, including preoperative diagnostic assessment, the localisation and extent of disease, and possibly the choice of treatment modalities by orthopaedic surgeons. We did a retrospective cohort study to characterise global surgical treatment protocols, and assess surgical outcomes, complications, and functional results in patients with diffuse-type tenosynovial giant-cell tumours. METHODS: In this international, multicentre, retrospective cohort study, we included consecutive patients treated in 31 sarcoma reference centres between Jan 1, 1990, and Dec 31, 2017. Eligible patients were of any age and had histologically proven diffuse-type tenosynovial giant-cell tumour of large joints. Patient data were retrieved from the local databases of participating centres. Patients with localised-type tenosynovial giant-cell tumour were excluded. In the analysis, we only included patients with complete core criteria data regarding admission status, date of treatment, type of treatment at participating centre, and first local recurrence after treatment. We used a non-parametric method to estimate recurrence-free survival at 3, 5, and 10 years after initial surgical resection in a tertiary centre. We used a multivariate Cox regression model to estimate the effect of risk factors. We also present subgroup analyses of disease status at presentation (primary vs recurrent disease) and recurrence-free survival by surgery type (open surgery vs arthroscopic synovectomy), and prespecified risk factors were tested in a univariate and multivariable analyses, with an endpoint of first local recurrence after treatment in a tertiary centre. FINDINGS: Data collection for these analyses occurred between January, 2016, and May, 2018. We received the records of 1192 patients, of which 966 (81%) were surgically treated and had complete information on core criteria. 445 patients were admitted with therapy-naive disease of the knee and were primarily treated in a tertiary centre. Since patients with wait and see treatment do not have a starting date of treatment, these patients were excluded in the calculation of median follow-up time for all patients. For this calculation we used time of surgery as a starting date. 758 (64%) of 1192 patients had knee involvement and 628 (54%) of 1163 patients with complete data on type of surgery had one-staged open synovectomy. At a median follow-up of 54 months (IQR 27-97), recurrent disease developed in 425 (44%) of all 966 surgically treated cases, and recurrence-free survival was 62% (95% CI 59-65) at 3 years, 55% (51-58) at 5 years, and 40% (35-45) at 10 years. Surgical complications were reported in 105 (12%) of 906 patients who had complete data on surgical complications. Pain improved after surgical treatment in 255 (59%) of 434 patients and swelling improved in 328 (72%) of 453 patients who had complete data. INTERPRETATION: This study of patients with diffuse-type tenosynovial giant-cell tumour provides a comprehensive and up-to-date disease overview, assessing the clinical profile and management of the disease in multiple specialised referral centres. Surgical treatment of diffuse-type tenosynovial giant cell tumours is not a definitive treatment for every patient because it involves a high risk for local recurrent disease and a relatively high risk for postoperative complications. After surgical treatment in treatment-naive patients, risk factors for recurrent disease in individual patients were not identified in what we believe is the largest cohort to date. FUNDING: Daiichi Sankyo.
Authors: Francisco Manuel Cañete Sánchez; Leonardo Gabriel Romero Robles; Xavier Louis Boulvard Chollet; María Mangas Losada; Puy Garrastachu; Antonio Cabrera Villegas; Rafael Ramírez Lasanta; Roberto Delgado Bolton Journal: Mol Imaging Radionucl Ther Date: 2022-06-27
Authors: Andrew C Chandler; Mohamed Yakoub; Tomohiro Fujiwara; Laura T Donlin; Paul Edward Purdue; John H Healey Journal: J Orthop Res Date: 2021-12-02 Impact factor: 3.102
Authors: James H Lewis; Hans Gelderblom; Michiel van de Sande; Silvia Stacchiotti; John H Healey; William D Tap; Andrew J Wagner; Antonio Lopez Pousa; Mihaela Druta; Chia-Chi Lin; Hideo A Baba; Youngsook Choi; Qiang Wang; Dale E Shuster; Sebastian Bauer Journal: Oncologist Date: 2020-12-24
Authors: Nicholas M Bernthal; Geert Spierenburg; John H Healey; Emanuela Palmerini; Sebastian Bauer; Hans Gelderblom; Eric L Staals; Julio Lopez-Bastida; Eva-Maria Fronk; Xin Ye; Petra Laeis; Michiel A J van de Sande Journal: Orphanet J Rare Dis Date: 2021-04-29 Impact factor: 4.123
Authors: J Lopez-Bastida; I Aranda-Reneo; B Rodríguez-Sánchez; L M Peña-Longobardo; X Ye; P Laeis; E M Fronk; E Palmerini; A Leithner; M A J Van de Sande Journal: Orphanet J Rare Dis Date: 2021-07-02 Impact factor: 4.123